Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Boudousq, Vincent ^a,b,c   Bobyk, Laure ^a,c   Busson, Muriel ^a,c   Garambois, Véronique ^a,c   Jarlier, Marta ^c   Charalambatou, Paraskevi ^a,c   Pèlegrin, André ^a,c   Paillas, Salomé ^a,c   Chouin, Nicolas ^d   Quenet, François ^c   Maquaire, Patrick ^e   Torgue, Julien ^e   Navarro Teulon, Isabelle ^a,c   Pouget, Jean Pierre ^a,c  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

^c CENTRE VAL D AURELLE   (France)

^d LUNAM UNIVERSITÉ   (France)

^e AREVA NP   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY PB 212; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SODIUM CHLORIDE; TRASTUZUMAB PB 212; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BLOOD TOXICITY; BODY WEIGHT; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; INTERNALIZATION; LEUKOCYTE COUNT; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY; THROMBOCYTE COUNT; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; FEMALE; HUMANS; LEAD RADIOISOTOPES; MICE; MICE, NUDE; PERITONEAL NEOPLASMS; RADIOIMMUNOTHERAPY; RECEPTOR, ERBB-2; RECEPTORS, CELL SURFACE;

EID: 84880785330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069613     Document Type: Article

References (58)

1. Ceelen WP, Flessner MF, (2010) Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 7: 108-115.
2. Glehen O, Mohamed F, Gilly FN, (2004) Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 5: 219-228.
3. Elias D, (2012) Is intraperitoneal chemotherapy after cytoreductive surgery efficient? Knowing whether it is or not appears secondary! Ann Surg Oncol 19: 5-6.
4. Sugarbaker PH, (2011) Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives? Am J Surg 201: 157-159.
5. Pomel C, Ferron G, Lorimier G, Rey A, Lhomme C, et al. (2010) Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol 36: 589-593.
6. Sugarbaker PH, (2009) Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach. Expert Opin Pharmacother 10: 1965-1977.
7. Glockzin G, Schlitt HJ, Piso P, (2009) Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 7: 5.
8. Bell JC, Rylah BG, Chambers RW, Peet H, Mohamed F, et al. (2012) Perioperative Management of Patients Undergoing Cytoreductive Surgery Combined with Heated Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: A Multi-Institutional Experience. Ann Surg Oncol.
9. Koppe MJ, Bleichrodt RP, Oyen WJ, Boerman OC, (2005) Radioimmunotherapy and colorectal cancer. Br J Surg 92: 264-276.
10. Aarts F, Hendriks T, Boerman OC, Koppe MJ, Oyen WJ, et al. (2007) A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol 14: 3274-3282.
11. Boudousq V, Ricaud S, Garambois V, Bascoul-Mollevi C, Boutaleb S, et al. (2010) Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies. J Nucl Med 51: 1748-1755.
12. Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, et al. (2009) Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med 50: 2033-2041.
13. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, et al. (2006) Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 24: 571-578.
14. Oei AL, Verheijen RH, Seiden MV, Benigno BB, Lopes A, et al. (2007) Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer 120: 2710-2714.
15. Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, et al. (2011) Clinical radioimmunotherapy-the role of radiobiology. Nat Rev Clin Oncol 8: 720-734.
16. Sharkey RM, Goldenberg DM, (2011) Cancer radioimmunotherapy. Immunotherapy 3: 349-370.
17. Boswell CA, Brechbiel MW, (2007) Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol 34: 757-778.
18. Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, et al. (1999) Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 40: 166-176.
19. Zhang Z, Zhang M, Garmestani K, Talanov VS, Plascjak PS, et al. (2006) Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood 108: 1007-1012.
20. Song H, Shahverdi K, Huso DL, Esaias C, Fox J, et al. (2008) 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res 68: 3873-3880.
21. Lingappa M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, et al. (2010) Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res 70: 6815-6823.
22. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, et al. (2000) An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 60: 6095-6100.
23. Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, et al. (2011) Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res 71: 1009-1018.
24. Li Y, Song E, Abbas Rizvi SM, Power CA, Beretov J, et al. (2009) Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates. Clin Cancer Res 15: 865-875.
25. Song EY, Qu CF, Rizvi SM, Raja C, Beretov J, et al. (2008) Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol Ther 7: 76-80.
26. Elgqvist J, Andersson H, Back T, Hultborn R, Jensen H, et al. (2005) Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. J Nucl Med 46: 1907-1915.
27. Gustafsson AM, Back T, Elgqvist J, Jacobsson L, Hultborn R, et al. (2012) Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model. Nucl Med Biol 39: 15-22.
28. Palm S, Back T, Claesson I, Danielsson A, Elgqvist J, et al. (2007) Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys 69: 572-579.
29. Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, et al. (2006) Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Nucl Med Biol 33: 1065-1072.
30. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, et al. (2005) Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 20: 557-568.
31. Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, et al. (2007) Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res 13: 1926-1935.
32. Almqvist Y, Steffen AC, Lundqvist H, Jensen H, Tolmachev V, et al. (2007) Biodistribution of 211At-labeled humanized monoclonal antibody A33. Cancer Biother Radiopharm 22: 480-487.
33. Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, et al. (2009) Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med 50: 1700-1708.
34. Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, et al. (1997) Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med 38: 1944-1950.
35. Tan Z, Chen P, Schneider N, Glover S, Cui L, et al. (2012) Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Int J Oncol 40: 1881-1888.
36. Milenic DE, Garmestani K, Brady ED, Baidoo KE, Albert PS, et al. (2008) Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res 14: 5108-5115.
37. Hudis CA, (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51.
38. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, et al. (1990) Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 50: 4221-4226.
39. Hammarstrom S, Shively JE, Paxton RJ, Beatty BG, Larsson A, et al. (1989) Antigenic sites in carcinoembryonic antigen. Cancer Res 49: 4852-4858.
40. Kohler G, Howe SC, Milstein C, (1976) Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur J Immunol 6: 292-295.
41. Robert B, Mach JP, Mani JC, Ychou M, Folli S, et al. (1996) Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. Cancer Res 56: 4758-4765.
42. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J, (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831.
43. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, et al. (2005) Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer biotherapy & radiopharmaceuticals 20: 557-568.
44. Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, et al. (2000) Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol 27: 93-100.
45. Yong K, Brechbiel MW, (2011) Towards translation of 212Pb as a clinical therapeutic; getting the lead in! Dalton Trans. 40: 6068-6076.
46. Dadachova E, Chappell LL, Brechbiel MW, (1999) Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nuclear medicine and biology 26: 977-982.
47. Tan Z, Chen P, Schneider N, Glover S, Cui L, et al. (2012) Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. International journal of oncology 40: 1881-1888.
48. Eckerman KF, Akira E, editors (2008) MIRD: Radionuclide Data and Decay Schemes. 671 p.
49. Chouin N, Bernardeau K, Davodeau F, Cherel M, Faivre-Chauvet A, et al. (2009) Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model. Radiat Res 171: 657-663.
50. Dahle J, Abbas N, Bruland OS, Larsen RH, (2011) Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates. Curr Radiopharm 4: 321-328.
51. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, et al. (2010) MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 51: 311-328.
52. Pouget JP, Santoro L, Raymond L, Chouin N, Bardies M, et al. (2008) Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res 170: 192-200.
53. Ruble G, Wu C, Squire RA, Ganswo OA, Strand M, (1996) The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. Int J Radiat Oncol Biol Phys 34: 609-616.
54. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, et al. (2002) Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100: 1233-1239.
55. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, et al. (2010) Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 16: 5303-5311.
56. Andersson H, Cederkrantz E, Back T, Divgi C, Elgqvist J, et al. (2009) Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2-a phase I study. J Nucl Med 50: 1153-1160.
57. Allen BJ, Singla AA, Rizvi SM, Graham P, Bruchertseifer F, et al. (2011) Analysis of patient survival in a Phase I trial of systemic targeted alpha-therapy for metastatic melanoma. Immunotherapy 3: 1041-1050.
58. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, et al. (2008) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49: 30-38.